LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

BioCryst Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

9.35 -3.11

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

9.19

Max

9.93

Pagrindiniai rodikliai

By Trading Economics

Pajamos

27M

32K

Pardavimai

14M

146M

Pelnas, tenkantis vienai akcijai

0

Pelno marža

0.022

Darbuotojai

580

EBITDA

22M

21M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+70.29% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-04

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

222M

2.1B

Ankstesnė atidarymo kaina

12.46

Ankstesnė uždarymo kaina

9.35

Naujienos nuotaikos

By Acuity

50%

50%

162 / 380 reitingas Healthcare

BioCryst Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-06-27 20:51; UTC

Uždarbis

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

2025-06-27 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-06-27 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-06-27 20:48; UTC

Rinkos pokalbiai

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

2025-06-27 20:46; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-06-27 20:46; UTC

Rinkos pokalbiai

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

2025-06-27 19:31; UTC

Rinkos pokalbiai

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

2025-06-27 19:19; UTC

Rinkos pokalbiai

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

2025-06-27 19:16; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

2025-06-27 18:57; UTC

Įsigijimai, susijungimai, perėmimai

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

2025-06-27 18:57; UTC

Įsigijimai, susijungimai, perėmimai

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

2025-06-27 18:57; UTC

Įsigijimai, susijungimai, perėmimai

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

2025-06-27 18:57; UTC

Įsigijimai, susijungimai, perėmimai

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

2025-06-27 18:57; UTC

Įsigijimai, susijungimai, perėmimai

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

2025-06-27 18:42; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-06-27 18:42; UTC

Rinkos pokalbiai

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

2025-06-27 18:39; UTC

Rinkos pokalbiai
Uždarbis

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

2025-06-27 18:29; UTC

Rinkos pokalbiai

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

2025-06-27 18:18; UTC

Rinkos pokalbiai

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

2025-06-27 18:16; UTC

Rinkos pokalbiai

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

2025-06-27 17:16; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

2025-06-27 17:08; UTC

Uždarbis

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

2025-06-27 16:52; UTC

Įsigijimai, susijungimai, perėmimai

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

2025-06-27 16:22; UTC

Uždarbis

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

2025-06-27 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-06-27 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-06-27 16:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-06-27 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-06-27 15:59; UTC

Rinkos pokalbiai

Gold Futures Slump on Improving Risk Appetite -- Market Talk

2025-06-27 15:56; UTC

Rinkos pokalbiai

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Akcijų palyginimas

Kainos pokytis

BioCryst Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

70.29% į viršų

12 mėnesių prognozė

Vidutinis 16.45 USD  70.29%

Aukščiausias 30 USD

Žemiausias 11 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines BioCryst Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

11 ratings

10

Pirkti

1

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

162 / 380 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.